Postmenopausal Bleeding: An Update



Abstract Views
1974

Downloads
3727

Citations

Share

##plugins.themes.bootstrap3.article.sidebar##

Submitted Jan 2, 2021
Published Jan 23, 2021
10.24018/ejmed.2021.3.1.652

Abstract viewed = 1974 times

Table of Contents

##plugins.themes.bootstrap3.article.main##

The clinical approach to postmenopausal bleeding requires prompt and efficient evaluation to exclude or diagnose endometrial carcinoma and endometrial intraepithelial neoplasia and to find out the real source. Postmenopausal bleeding is ‘endometrial cancer until proven otherwise’, although only 1-14% of such patients will actually have cancer. Clinical risk factors of endometrial carcinoma such as obesity, unopposed estrogen use, polycystic ovary syndrome, diabetes mellitus and family history of gynaecologic malignancy also should be considered during evaluation. Postmenopausal bleeding usually attributed to an intrauterine source, but it may arise from the cervix, vagina, vulva or fallopian tubes & ovaries. The origin of bleeding can also involve non-gynaecologic sites, such as the urethra, bladder, anus/rectum/bowel, or perineum.

Meticulous history and thorough physical examination are must. Initial evaluation is by TVS, if endometrial thickness (ET) is <4mm no further evaluation is required but follow up consultation must. If ET is> 4mm, hysteroscopic evaluation and endometrial sampling is recommended

Blind endometrial sampling is not accurate as only reveals when endometrial cancer exceeds more than 50% of the endometrial surface area so may be done if hysteroscopic evaluation is not possible. Higher dose of progesterone may be required for endometrial protection when higher doses of estradiol as hormone replacement therapy are used, or in women with high BMI. Unopposed estrogen therapy is associated with a duration and dose-related increase in risk of endometrial hyperplasia and cancer. Endometrial protection requires an adequate dose and duration of progestogen. Endometrial hyperplasia with atypia has much malignant potential but endometrial hyperplasia without atypia may be managed medically with 3 monthly endometrial sampling, if no regression or further progression hysterectomy is the choice of treatment. Finally, patient counseling with discussion of risks /benefits of different options of treatment modalities is the cornerstone of success of addressing postmenopausal bleeding.

Keywords: Endometrial thickness, endometrial hyperplasia, endometrial cancer, postmenopausal bleeding

Downloads

Download data is not yet available.

References

  1. Moodley M, Roberts C. Clinical pathway for the evaluation of postmenopausal bleeding with an emphasis on endometrial cancer detection. J Obstet Gynaecol 2004; 24:736.
    DOI  |   Google Scholar
  2. Prendergast EN, Misch E, Chou YA, et al. Insufficient endometrial biopsy results in women with abnormal uterine bleeding. Obstet Gynecol 2014; 123 Suppl 1:180S.
    DOI  |   Google Scholar
  3. Ferenczy A. Pathophysiology of endometrial bleeding. Maturitas 2003; 45:1.
    DOI  |   Google Scholar
  4. Van Hanegem N, Breijer MC, Khan KS, et al. Diagnostic evaluation of the endometrium in postmenopausal bleeding: an evidence-based approach. Maturitas 2011; 68:155.
     Google Scholar
  5. Cote ML, Ruterbusch JJ, Ahmed Q, et al. Endometrial cancer in morbidly obese women: do racial disparities affect surgical or survival outcomes? Gynecol Oncol 2014; 133:38.
    DOI  |   Google Scholar
  6. Salman MC, Bozdag G, Dogan S, Yuce K. Role of postmenopausal bleeding pattern and women's age in the prediction of endometrial cancer. Aust N Z J Obstet Gynaecol 2013; 53:484.
    DOI  |   Google Scholar
  7. Lee-may Chen, MD Jonathan S Berek, MD, MMS; Endometrial carcinoma: Epidemiology, risk factors, and prevention: UpTodate Nov 9, 2020.
     Google Scholar
  8. Clarke MA, Long BJ, Del Mar Morillo A, et al. Association of Endometrial Cancer Risk with Postmenopausal Bleeding in Women: A Systematic Review and Meta-analysis. JAMA Intern Med 2018; 178:1210.
    DOI  |   Google Scholar
  9. Tanos V, Berry KE, Seikkula J, Abi Raad E, Stavroulis A, Sleiman Z, Campo R, Gordts S. The management of polyps in female reproductive organs. Int J Surg. 2017 Jul; 43:7-16.
    DOI  |   Google Scholar
  10. Lee SC, Kaunitz AM, Sanchez-Ramos L, Rhatigan RM. The oncogenic potential of endometrial polyps: a systematic review and meta-analysis. Obstet Gynecol. 2010 Nov;116(5):1197-205. [PubMed].
    DOI  |   Google Scholar
  11. Elfayomy AK, Soliman BS. Risk Factors Associated with the Malignant Changes of Symptomatic and Asymptomatic Endometrial Polyps in Premenopausal Women. J Obstet Gynaecol India. 2015 May;65(3):186-92.
    DOI  |   Google Scholar
  12. Maia H, Barbosa IC, Marques D, Calmon LC, Ladipo OA, Coutinho EM. Hysteroscopy and transvaginal sonography in menopausal women receiving hormone replacement therapy. J Am Assoc Gynecol Laparosc. 1996 Nov;4(1):13-8.
    DOI  |   Google Scholar
  13. Hassa H, Tekin B, Senses T, Kaya M, Karatas A. Are the site, diameter, and number of endometrial polyps related with symptomatology? Am J Obstet Gynecol. 2006 Mar;194(3):718-21.
    DOI  |   Google Scholar
  14. American Association of Gynecologic Laparoscopists. AAGL practice report: practice guidelines for the diagnosis and management of endometrial polyps. J Minim Invasive Gynecol. 2012 Jan-Feb;19(1):3-10.
    DOI  |   Google Scholar
  15. Hedrick Ellenson L, Ronnett BM, Kurman RJ. Precursor Lesions of Endometrial Carcinoma. In: Blaustein's Pathology of the Female Genital Tract, 6th ed, Kurman RJ, Hedrick Ellenson L, Ronnett, BM (Eds), Springer, New York 201.
     Google Scholar
  16. Paramsothy P, Harlow SD, Greendale GA, et al. Bleeding patterns during the menopausal transition in the multi-ethnic Study of Women's Health Across the Nation (SWAN): a prospective cohort study. BJOG 2014; 121:1564.
    DOI  |   Google Scholar
  17. Shoff SM, Newcomb PA. Diabetes, body size, and risk of endometrial cancer. Am J Epidemiol 1998; 148:234.
    DOI  |   Google Scholar
  18. Van Hunsel FP, Kampschöer P. [Postmenopausal bleeding and dietary supplements: a possible causal relationship with hop- and soy-containing preparations]. Ned Tijdschr Geneeskd 2012; 156: A5095.
     Google Scholar
  19. Sabadell J, Castellví J, Baró F. Tuberculous endometritis presenting as postmenopausal bleeding. Int J Gynaecol Obstet 2007; 96:203.
    DOI  |   Google Scholar
  20. Mengistu Z, Engh V, Melby KK, et al. Postmenopausal vaginal bleeding caused by endometrial tuberculosis. Acta Obstet Gynecol Scand 2007; 86:631.
    DOI  |   Google Scholar
  21. Güngördük K, Ulker V, Sahbaz A, et al. Postmenopausal tuberculosis endometritis. Infect Dis Obstet Gynecol 2007; 2007:27028.
    DOI  |   Google Scholar
  22. Van Hanegem N, Breijer MC, Khan KS, et al. Diagnostic evaluation of the endometrium in postmenopausal bleeding: an evidence-based approach. Maturitas 2011; 68:155-64.
    DOI  |   Google Scholar
  23. American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 440: The Role of Transvaginal Ultrasonography in the Evaluation of Postmenopausal Bleeding. Obstet Gynecol 2009; 114:4.
    DOI  |   Google Scholar
  24. Goldstein SR, Nachtigall M, Snyder JR, et al. Endometrial assessment by vaginal ultrasonography before endmetrial sampling in patients with postmenopausal bleeding. Am J Obstet Gynecol 1990; 163:119–23.
    DOI  |   Google Scholar
  25. Varner RE, Sparks JM, Cameron CD, et al. Transvaginal sonography of the endometrium in postmenopausal women. Obstet Gynecol 1991; 78:195–9.
     Google Scholar
  26. Granberg S, Wikland M, Karlsson B, et al. Endometrial thickness as measured by endovaginal ultrasonography for identifying endometrial abnormality. Am J Obstet Gynecol 1991; 164:47–52.
    DOI  |   Google Scholar
  27. Gull B, Karlsson B, Milsom I et al. Can ultrasound replace diltation and curettage? A longitudinal evaluation of postmenopausal bleeding and transvaginal sonographic measurement of the endometrium as predictors of endometrial cancer. Am J Obstet Gynecol 2003; 188:401.
    DOI  |   Google Scholar
  28. Epstein E, Ramirez A, Skoog L, Valentin L. Dilatation and curettage fails to detect most focal lesions in the uterine cavity in women with postmenopausal bleeding. Acta Obstet Gynecol Scand 2001; 80:1131.
    DOI  |   Google Scholar
  29. Wang J, Wieslander C, Hansen G, et al. Thin endometrial echo complex on ultrasound does not reliably exclude type 2 endometrial cancers. Gynecol Oncol 2006; 101:120.
    DOI  |   Google Scholar
  30. Chandavarkar U, Kuperman J, Muderspach L, et al. Postmenopausal endometrial cancer: Reevaluating the role of endometrial echo complex. Gynecol Oncol 2011; 120:S11.
    DOI  |   Google Scholar
  31. http://seer.cancer.gov/csr/1975_2007/browse_csr.php?section=5&page=sect_05_table.07.html (Accessed on March 14, 2011).
     Google Scholar
  32. Partridge EE, Abu-Rustum NR, Campos SM, et al. Cervical cancer screening. J Natl Compr Canc Netw 2010; 8:1358.
    DOI  |   Google Scholar
  33. Rosen MW, Tasset J, Kobernik EK, et al. Risk Factors for Endometrial Cancer or Hyperplasia in Adolescents and Women 25 Years Old or Younger. J Pediatr Adolesc Gynecol 2019; 32:546.
    DOI  |   Google Scholar
  34. Vetter MH, Smith B, Benedict J, et al. Preoperative predictors of endometrial cancer at time of hysterectomy for endometrial intraepithelial neoplasia or complex atypical hyperplasia. Am J Obstet Gynecol 2020; 222:60. e1.
    DOI  |   Google Scholar
  35. Karlsson B, Granberg S, Wikland M, et al. Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding--a Nordic multicenter study. Am J Obstet Gynecol 1995; 172:1488.
    DOI  |   Google Scholar
  36. Emons G, Beckmann MW, Schmidt D, et al. New WHO Classification of Endometrial Hyperplasias. Geburtshilfe Frauenheilkd 2015; 75:135.
    DOI  |   Google Scholar
  37. Gallos ID, Shehmar M, Thangaratinam S, et al. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 2010; 203:547. e1.
    DOI  |   Google Scholar
  38. Abu Hashim H, Ghayaty E, El Rakhawy M. Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia: a systematic review and metaanalysis of randomized trials. Am J Obstet Gynecol 2015; 213:469.
    DOI  |   Google Scholar
  39. Rakha E, Wong SC, Soomro I, et al. Clinical outcome of atypical endometrial hyperplasia diagnosed on an endometrial biopsy: institutional experience and review of literature. Am J Surg Pathol 2012; 36:1683.
    DOI  |   Google Scholar
  40. Reed SD, Newton KM, Garcia RL, et al. Complex hyperplasia with and without atypia: clinical outcomes and implications of progestin therapy. Obstet Gynecol 2010; 116:365.
    DOI  |   Google Scholar
  41. Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol 2012; 125:477.
    DOI  |   Google Scholar
  42. Gallos ID, Krishan P, Shehmar M, et al. Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up. Hum Reprod 2013; 28:1231.
    DOI  |   Google Scholar
  43. Suckling JA, Kennedy R, Lethaby A, et al. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database of Syst Rev 2006, (4).
    DOI  |   Google Scholar